Pay in 4 interest-free payments of $6.62 Learn more
Ships within 48 hours · Estimated delivery Nov 12 - Nov 17
Compound class Synthetic cyclic melanocortin peptide Primary therapeutic relevance Central sexual-desire signaling Approved product VYLEESI bremelanotide injection FDA approval date June 21, 2019 Approved population Premenopausal women with acquired, generalized HSDD Not approved for Men, postmenopausal women, ED, or performance enhancement Terminology clarification: PT-141 generally refers to bremelanotide free base or the active peptide, while the approved drug product contains bremelanotide acetate in a specific sterile injectable formulation
(Placental equilibration by week 7.) Sherwin CMT, et al
Glowing, Youthful Skin
Environmental Conditions : The temperature variations can significantly impact battery performance and safety and we design our battery packs to perform optimally across a wide range of environmental conditions
US$ 25.94
US$ 22.31
US$ 25.58
US$ 22.24
US$ 29.72
